TKPHF (Takeda Pharmaceutical Co) Marketable Securities: $414 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TKPHF Takeda Pharmaceutical Co Ltd TKPHF
77 GF Score
Price $35.89
GF Value $29.62
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Takeda Pharmaceutical Co Marketable Securities?

Takeda Pharmaceutical Co TKPHF +2.72% 77 Marketable Securities is $414 Mil as of Jun. 2026. GuruFocus rates TKPHF with a GF Score™ of 77/100 and a GF Value™ of $29.62 (Significantly Overvalued). The stock has 10 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Takeda Pharmaceutical Co's Marketable Securities for the quarter that ended in Jun. 2026 was $414 Mil.

Takeda Pharmaceutical Co's annual Marketable Securities increased from Mar. 2024 ($101 Mil) to Mar. 2025 ($137 Mil) and increased from Mar. 2025 ($137 Mil) to Mar. 2026 ($264 Mil).

Takeda Pharmaceutical Co  (OTCPK:TKPHF) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Takeda Pharmaceutical Co Marketable Securities Related Terms

Takeda Pharmaceutical Co Marketable Securities Historical Data

* Premium members only.

The historical data trend for Takeda Pharmaceutical Co's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Takeda Pharmaceutical Co Marketable Securities Chart

Takeda Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 213.41 150.93 100.72 137.37 263.97

Takeda Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 478.72 393.55 686.30 263.97 414.26
TKPHF
77GF Score
Takeda Pharmaceutical Co Ltd TKPHF
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Takeda Pharmaceutical Co Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $414 Mil mean?
Takeda Pharmaceutical Co (TKPHF) has a Marketable Securities of $414 Mil as of Jun. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Takeda Pharmaceutical Co and its competitors.
Is Takeda Pharmaceutical Co's Marketable Securities too high?
Takeda Pharmaceutical Co's current Marketable Securities is $414 Mil. Overall, Takeda Pharmaceutical Co has a GF Score™ of 77/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Takeda Pharmaceutical Co's Marketable Securities compare to ZTS and UTHR?
Takeda Pharmaceutical Co's Marketable Securities of $414 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Drug Manufacturers company?
A good Marketable Securities depends on the Drug Manufacturers industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Takeda Pharmaceutical Co and its competitors. Takeda Pharmaceutical Co's current Marketable Securities is $414 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Takeda Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Takeda Pharmaceutical Co (TKPHF) is currently considered Significantly Overvalued. The stock's GF Value™ is $29.62, compared to a current price of $35.89 — trading 21.2% above its estimated fair value. The current Marketable Securities is $414 Mil. Takeda Pharmaceutical Co's overall GF Score™ is 77/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Takeda Pharmaceutical Co (TKPHF), the current Marketable Securities is $414 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Takeda Pharmaceutical Co (TKPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Takeda Pharmaceutical Co stock appears to be overvalued. The current stock price of $35.89 is trading 21.2% above its estimated GF Value™ of $29.62. GuruFocus considers Takeda Pharmaceutical Co to be Significantly Overvalued.

Key valuation signals for TKPHF:

  • Marketable Securities: $414 Mil
  • GF Value™: $29.62 vs. price of $35.89 (21.2% above fair value)
  • GF Score™: 77/100 with 10 warning signs

No single metric tells the full story. See the TKPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Takeda Pharmaceutical Co Business Description

Address 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, JPN, 103-8668
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
77GF Score

Get the complete analysis for TKPHF

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$35.89
Price
$29.62
GF Value